Eikon Therapeutics’ Post

🚀 New customer case study alert! 🚀 🌐💡The recent work of Valentina Paloschi and her collaborators showcasing Fluigent’s Microfluidic Flow Control System is truly groundbreaking! 🩸By ingeniously creating an Artery-on-chip model, they've successfully replicated the structure of medium-to-large size arteries and deciphered their response to hemodynamic forces. 💊The AoC model not only mimics arteries but also serves as an advanced platform for predictive drug testing, offering insights into the effects of therapeutic agents used in preclinical studies! 🔍Read more about this exciting research here: https://bit.ly/3UT1oaE #Microfluidics #BiotechInnovation #DrugDiscovery #ScienceAdvancement

Exciting news from our Alcor 7th Drug Discovery Platform event at the Princeton Crown Plaza in New Jersey! Demet Aybar, CEO of US Lab Partners LLC, is currently delivering a captivating presentation. Topic: Empowering Drug Platform Development: A Roadmap to Acceleration Demet Aybar, the dynamic Founder and CEO of US Lab Partners LLC and DKScientific, is a prominent figure recognized by Marquis Who’s Who Top Executives for her outstanding dedication, achievements, and leadership in laboratory administration. With a profound focus on analytical chemistry and a wealth of experience in operational management, cell culture, high throughput screening, quality assurance, and assay development, Demet emerges as a highly motivated and detail-oriented leader within the biotechnology industry. Stay tuned for insights from Demet's presentation, offering invaluable perspectives on accelerating drug platform development. This is a momentous opportunity to learn from one of the industry's most driven and accomplished leaders! #ADDP2024 #7thADDP #Alcordrugdiscoveryplatform #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits  #DrugDiscoverySummits #EuropeanClinicalTrialSummits #Scientist #DrugDiscovery #Preclinical #Medchem #Biology #Protein #Antibodies #Conference #InPersonEvent #Summit #AI #ML #Data #Oncology #DrugDevelopment #Collaboration #Keynote #PanelDiscussion #Oncology #Therapeutics #DrugDesign #SmallMolecules #LargeMolecules #Events #Therapeutics #BigData #Marketing #DigitalMarketing #AIdrug #alcordrug #alcordiscovery #addp2024

Unveiling the Future of Predicting Drug Reactogenicity Imagine reducing some of the uncertainty in #drugdevelopment. Our latest study using the ImmunoSafe® platform brings this vision closer to reality. We have successfully mapped the secretomic response to Cetrotide® injections in human skin models. This breakthrough illustrates the power of combining bio-stabilized human skin with bioinformatic analysis, offering new perspectives on drug reactogenicity. Our findings have major implications for enhancing the safety and efficacy of injectable drugs. 🧐 Intrigued? Download our detailed poster to explore how our research is paving the way for safer, more efficient drug development. https://lnkd.in/ehh38D77

In partnership with Sartorius, our colleagues Harshita Londhe and Abijar Bhori, have co-authored an insightful application note titled: Intensifying a mAb Polishing Platform — Targeting Time, Cost, and Space Efficiency.   This note sheds light on the compelling advantages of process intensification, offering solutions to address key challenges in the production of biologics, including low productivity, high resin costs, lengthy timelines, and substantial facility footprint.   Click on the link below and discover how innovation can drive time, cost, and space efficiency in biologics production. Intensifying a mAb Polishing Platform - Targeting Time, Cost, and Space Efficiency (https://lnkd.in/e6ukJT2p)   #enzenebiosciences #innovation #processintensification #biologics #EnzeneX™   Sartorius Stedim Biotech Enzene Biosciences Ltd Sanket Jadhav, PhD Ganesh Kumar buwadas raut Harshita Londhe, Abijar Bhori

I am delighted to present Lifebit's latest white paper, offering comprehensive insights into the transformative capabilities of our Drug Discovery module. Explore the methodologies and findings that are reshaping the landscape of drug development. Dive deep into the whitepaper for an in-depth understanding: https://bit.ly/3HVpaLx #DrugDiscoveryWorkflows #Pharma #Lifebit

Paul Turner (Yale University) and colleagues have written a new review on gaps in modern phage therapy R&D. It includes some fun exploration of how AI & synbio could ease phage therapy logistics, a walkthrough of how and why new funding & regulatory models would help, an overview of how local phage centers and small biotechs are pushing phage therapy forward in the absence of large pharma, and more. Great read!

180 Life Sciences is on a mission to see if the anti-TNF technology that produced a blockbuster could work for a range of other conditions. PharmaVoice’s Kelly Bilodeau speaks with 180 Life Sciences’ CEO Dr. James Woody to discuss his experience and new frontiers for anti-TNF treatment. Read the full article here: https://lnkd.in/gEJea3wj #Science #Biotech #LifeSciences

Are you planning your iPSC collaborations for 2024? Our team have our lab notebooks out and ready! Here's how we can help: Axol's scientists have been working on iPSCs and their applications in neurodegenerative/inflammatory drug discovery for 10 years! We've made all the mistakes so you don't have to. Our scientists have over 100 years combined experience and came from large biopharma companies to join Axol in developing the world's leading iPSC models. We can accelerate you towards the data you need for IND submissions and more. Let us know what you're thinking about trying, and we'll tell you our thoughts on feasibility, budget, and timeline. Set up a time to talk here: https://lnkd.in/eybSP2Ah To find out more, read our blog post here: https://lnkd.in/ecchxWrt #iPSCs #StemCells #DrugDiscovery #BetterHumanDiseaseModels #hiPSCs 

Our latest blog post, "Finding new active molecule 6x faster with DeepMirror" is live! Optimising ADMET properties is an essential step in drug discovery and is a major cause of clinical drug failure. In our latest blogpost, we show how a European biotech, previously stuck with scaffolds with good potency but adverse ADMET, used DeepMirror to identify new highly potent molecular scaffolds with better ADMET properties in 2 weeks instead of 3 months. You can read it here: https://lnkd.in/dicU-BWx